

**Supplementary Table 1.** Baseline and perioperative variables between patients with and without postoperative non-steroidal anti-inflammatory drugs (NSAIDs) use before and after inverse probability of treatment weighting in the total cohort

Characteristics	Before weighting			After weighting		
	No NSAID group (n=1,914)	NSAID group (n=222)	SMD	No NSAID group (n=2,136)	NSAID group (n=1,875)	SMD
<b>Demographic data</b>						
Current smoker	285 (14.9)	37 (16.7)	0.049	320 (15.0)	304 (16.2)	0.034
<b>Background medical status</b>						
Pathology			0.112			0.164
Pancreatic cancer	786 (41.1)	83 (37.4)		871 (40.7)	718 (38.3)	
Distal CBD cancer	389 (20.3)	49 (22.1)		435 (20.4)	414 (22.1)	
AoV cancer	343 (17.9)	46 (20.7)		384 (18.0)	426 (22.7)	
Duodenal cancer	48 (2.5)	7 (3.2)		54 (2.5)	54 (2.9)	
Neuroendocrine tumor	149 (7.8)	16 (7.2)		169 (7.9)	120 (6.4)	
Benign diseases	104 (5.4)	10 (4.5)		116 (5.4)	734 (4.0)	
Others	95 (5.0)	11 (5.0)		108 (5.0)	68 (3.6)	
Preoperative bilirubin (mg/dL)	0.8 (0.5–1.6)	0.8 (0.5–1.6)	0.065	0.8 (0.5–1.6)	0.8 (0.5–1.6)	0.053
Neoadjuvant radiation therapy	61 (3.2)	7 (3.2)	0.002	65 (3.0)	94.1 (5.0)	0.101
Preoperative biliary drainage	238 (12.4)	32 (14.4)	0.058	264 (12.4)	254 (13.6)	0.036
<b>Operation and anesthesia related</b>						
Total intravenous anesthesia (vs. inhalation anesthesia)	303 (15.8)	33 (14.9)	0.027	333 (15.6)	313 (16.7)	0.030
Intraoperative vasopressor use	1,544 (80.7)	180 (81.1)	0.010	1,722 (80.6)	1,507 (80.4)	0.006
Colloid administration, mL	0 (0–500)	0 (0–500)	0.018	0 (0–500)	0 (0–500)	0.037
pRBC transfusion, n	278 (14.5)	27 (12.2)	0.070	309 (14.5)	218 (11.6)	0.085
Epidural patient controlled analgesia	21 (1.1)	5 (2.3)	0.090	23 (1.1)	34 (1.8)	0.060

The values are presented as the median (interquartile range) or number (%). BMI, Body mass index; AoV, Ampulla of Vater; ASA, American Society of Anesthesiologists; CBD, Common bile duct; PPPD, pylorus-preserving pancreaticoduodenectomy; pRBC, packed red blood cell; SMD, standardized difference.